🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO24 Dr. Prof Tom John shows #MRD analysis from ADAURA (adjuvant osimertinib for #EGFR NSCLC). This is a tumor-informed MRD assay (individual for each patient).

ctDNA can be a powerful tool to detect relapse before radiographic PD. Terrific presentation by Prof Tom John ASCO #ASCO24 MRD+ detected relapse 4.7 month earlier, and further work needs to be done to select the pts for escalation of tx #LCSM OncoAlert

CheckMate-77T update ❓Is neo-adj chemoIO appropriate with N2 (poorer prog) St3 ✅ EFS maintained HR 0.60 (N2) v 0.60 (non-N2) ✅ 67% w N2 had nodal downstaging ✅ N2 w/o pCR = ⬆️EFS w Niv HR 0.48 🤔 If resectable, N2 not a reason per se to avoid neo-adj chemoIO #ASCO24 #LCSM

Really important stage shift shown in Taiwan National Lung screen program. Bravo Dr PC Yang! Family hx is a key risk factor. Excited to collaborate with Allison Chang and Jill Feldman to open a clinical trial soon focused on screening in those w/ a positive family hx #ASCO24

Love to see Steven Vogl back at the 🎤! Icotinib soaking into those cells?@DrSteveMartin New York Lung Cancer Foundation

Interesting stuff Charu Aggarwal, MD, MPH, FASCO Daniel Sterman !

Sorry I missed the photo op! Great seeing you all! Fred R. Hirsch The Tisch Cancer Institute New York Lung Cancer Foundation Mount Sinai Hematology/Oncology Fellowship Triparna Sen (Sen-Lab)

What a great overview. Thanks for teaching me Julia Rotow MD !

Come hang out with a bunch of smart Mount Sinai Thoracic Oncology & Weill Cornell Medicine Cardiothoracic Surgery docs and learn about new data in lung cancer. Deborah Doroshow . Mount Sinai Hematology/Oncology Fellowship The Tisch Cancer Institute @JonvillenaM Christian Rolfo urldefense.proofpoint.com/v2/url?u=https…

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. Adrien Rousseau sciencedirect.com/science/articl…

What is the role for SRS to brain metastases up front for #EGFR or #ALK NSCLC? Retrospective TURBO-NSCLC study Journal of Clinical Oncology shows early radiation improves CNS control but not survival when CNS-penetrant TKIs are used. Greater benefit with larger tumors. ascopubs.org/doi/10.1200/JC…

Happy 50th IASLC! Congrats to the co-chairs on organizing a spectacular #WCLC24 meeting & awesome celebration! Great first meeting experience! Narjust Florez, MD, FASCO Linda Martin Sandip Patel MD FASCO Dr. Fabio Moraes Ashish Saxena, MD, PhD Elaine Shum Chris Martin Maria Antonia Vélez Morana Vojnic, MD, MBA Nick Rohs, MD

Come join in the fun with me, Balazs Halmos, and a hippo-load of amazing thoracic oncs reviewing all the new data (hint: there’s a lot!). Mount Sinai Thoracic Oncology Mount Sinai Hematology/Oncology Fellowship

Excellent paper! Includes England lung cancer never smoking freq by ethnicity. 6.7% of lung cancer are never smokers in White, 38.3% in Indian, 31.6% in Pakistani, 11.3% in Bangladeshi, 14.9% in Caribbean, 39.2% in Black African, & 44.5% in Chinese ethnicities Ruth Strauss Foundation

Proud of Rodrigo Paredes, MD presenting at #HTTR24 our data on value of ctDNA in EGFR first line. VAF as predictive biomarker of DFS in Osimertinib treatment. IASLC Deborah Doroshow Nick Rohs, MD Fred R. Hirsch Mount Sinai Thoracic Oncology The Tisch Cancer Institute Ohio State Medical Oncology

Great talks - great panel discussions - tackling the real world issues of moving lung cancer care forward Fred R. Hirsch New York Lung Cancer Foundation Christian Rolfo

What a great team. A bunch of my New York Lung Cancer Foundation buddies !

Thanks for joining us Meyer May-Lucie New York Lung Cancer Foundation !

🔑 #LungCancer #ClinicalTrials at #AACR25 ! Zongertinib in pretreated HER2 mut. NSCLC: Beamion LUNG-1 🔹ORR 71% (7% CR) with mDOR 14.1 mo 🔹mPFS 12.4 mo (95% CI, 8.2 to NR) 🔹Intracranial ORR 41% 🔹Pretx with HER2 ADC (cohort 5; n=31) ORR 48% 🔹Improved AE profile compared to

Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R) buff.ly/Pj4cQv4 In the SUPE_R multicenter randomized trial, researchers compared [18F]FDG PET/CT with contrast-enhanced CT (ceCT) for post-treatment